On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.
In this type of cancer therapy, a patient’s own T-cells, a type of immune cell, are collected from a blood draw and genetically modified in the lab so that they can recognize proteins on tumor cells. After infusion back into the patient, the CAR T-cells kill the targeted cancer cells.
The work will be led by principal investigator Ezra Cohen, MD, professor at UC San Diego School of Medicine, associate director for clinical science and chief of the Division of…
News Source: https://www.news-medical.net/news/20211124/CIRM-awards-2441-million-to-advance-CAR-T-cell-therapy-from-the-lab-to-clinic.aspx